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Abstract
Genome-wide association studies (GWAS) have successfully identified a number of single-nucleotide polymorphisms (SNPs)
associated with colorectal cancer (CRC) risk. However, these susceptibility loci known today explain only a small fraction of
the genetic risk. Gene-gene interaction (GxG) is considered to be one source of the missing heritability. To address this, we
performed a genome-wide search for pair-wise GxG associated with CRC risk using 8,380 cases and 10,558 controls in the
discovery phase and 2,527 cases and 2,658 controls in the replication phase. We developed a simple, but powerful method
for testing interaction, which we term the Average Risk Due to Interaction (ARDI). With this method, we conducted a
genome-wide search to identify SNPs showing evidence for GxG with previously identified CRC susceptibility loci from 14
independent regions. We also conducted a genome-wide search for GxG using the marginal association screening and
examining interaction among SNPs that pass the screening threshold (p,10
24). For the known locus rs10795668 (10p14),
we found an interacting SNP rs367615 (5q21) with replication p=0.01 and combined p=4.19610
28. Among the top
marginal SNPs after LD pruning (n=163), we identified an interaction between rs1571218 (20p12.3) and rs10879357
(12q21.1) (nominal combined p=2.51610
26; Bonferroni adjusted p=0.03). Our study represents the first comprehensive
search for GxG in CRC, and our results may provide new insight into the genetic etiology of CRC.
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Introduction
Genome-wide association studies (GWAS) have successfully
identified single-nucleotide polymorphisms (SNPs) associated with
colorectal cancer (CRC) [1–10]. As biologic candidates, those
findings have enhanced our understanding of the genetic etiology
of CRC. However, the susceptibility loci found so far explain only
a small fraction of the genetic risk: the ‘‘missing heritability’’
problem [7]. Among other explanations, the lack of a compre-
hensive examination of gene-gene interaction (GxG) is often
considered as one possible source for the unexplained heritability
[11–14]. A recent paper also suggests that the missing heritability
problem could be due to the overestimation of additive heritability
if the assumption that there is no GxG or GxE interaction is
incorrect [15]. The standard GWAS test for association is to use a
single-locus approach, testing one SNP at a time across the entire
genome; however, the underlying genetic mechanism of a complex
disease, like CRC, probably involves interplays among multiple
loci. Testing each locus individually without considering other loci
with which it may interact may miss true genetic effects.
Compared to the single-locus approach, there have been very
few genome-wide examinations of GxG, probably at least partially
due to the limited availability of individual-level large-scale GWAS
data and analytical difficulties and limitations in computation
given the massive number of possible interactions. A genome-wide
study of psoriasis has reported compelling evidence for an
interaction between variants at the HLA-C and ERAP1 loci [16].
Another study identified a GxG between a previously identified
locus C1orf106 and a new locus TEC for Crohn’s disease, with the
interaction successfully replicated in an independent dataset [17].
So far, no GxG has been identified for CRC.
In this paper, we focus on testing pair-wise GxG for CRC using
GWAS data in the Genetics and Epidemiology of Colorectal
Cancer Consortium (GECCO) and the Colon Cancer Family
Registry (CCFR) with a total sample size of 10,907 cases and
13,216 controls. We present a simple, but powerful method for
testing interaction: the Average Risk Due to Interaction (ARDI).
We performed a genome-wide search to identify SNPs interacting
with previously identified CRC susceptibility loci in 14 indepen-
dent regions (rs6687758/1q41, rs10936599/3q16.2, rs16892766/
8q23.3, rs6983267/8q24, rs10795668/10p14, rs3802842/11q23,
rs7136702/12q13.13, rs4444235/14q22.2, rs4779584/15q13,
rs9929218/16q22.1, rs4939827/18q21, rs10411210/19q13,
rs961253/20p12.3, rs4925386/20q13.33) [1–10]. We gave prior-
ity to these known susceptibility loci because they have been
confirmed to be associated with CRC risk in previous studies. We
also conducted a genome-wide search for pair-wise GxG. In order
to alleviate the computational burden and reduce the number of
multiple comparisons, we used marginal association screening and
examined only pairwise interactions among the SNPs passing that
screen.
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GxG for 14 known CRC Susceptibility Loci
After applying the QC and selection criteria, there were a total
of 2,011,668 SNPs in common among studies in the Phase I
studies (Materials and Methods; Table 1).
We selected interactions that have fixed-effect meta-analysis p-
values ,10
26 in Phase I for replication in Phase II. These
interactions are summarized in Table 2. For SNPs that are in LD
(r
2.0.8), we reported only the most significant interacting SNP.
Overall we identified 12 interactions with p,10
26 in Phase 1,
including three interacting SNPs selected for each of the known
loci rs6687758, rs4925386; two interacting SNPs selected for
known locus rs7136702, and one interacting SNP for each of
known locus rs4779584, rs10795668, rs9929218, and rs961253,
respectively.
Within Phase II, the interaction between known loci
rs10795668 and rs367615 showed evidence for replication
(OR=0.76, 95% CI 0.61–0.95; p=0.01) with a combined Phase
I and II OR of 0.74 (95%CI 0.67–0.83; p=4.19610ˆ-8). rs367615
is located on 5q21 and has a MAF of 0.22 in CEU population.
Additional inclusion of two advanced colorectal adenoma studies
in the replication study further strengthened the statistical
significance level of the replication (OR=0.78 and 8.97610
23);
OR and p-value for Phase I, II and advanced adenoma studies
combined are 0.75 and 2.88610
28. rs10795668 was genotyped in
10 studies and imputed in 11 studies with average imputation R
2
of 0.97 (range from 0.92 to 1.00); rs367615 was genotyped in 4
studies and imputed in 17 studies with average R
2 of 0.98 (range
from 0.91 to 1.00). The forest plot showing individual study results
is presented in Figure 1. We did not observe evidence for
heterogeneity, and random effects results are similar to fixed
effects results for this interaction. Figure 2 shows the regional
association plot. Several LD partners of rs367615 also show
evidence of interaction with rs10795668.
We also examined the two-locus interaction pattern for the SNP
pair described above using a unrestricted model. Table 3(a)
summarizes the OR and sample size for each genotype
combination relative to the reference genotypes for Phase I and
II studies combined. Table 3(b) and Table 3(c) summarize the OR
for each SNP stratified by the genotypes of the other. In Table 3,
we can see that subjects who carry AG genotype for rs10795668
and CT genotypes for rs367615 have a statistically significantly
increased disease risk compared to those who carry reference
genotypes at both loci (rs10795668:GG/rs367615:TT). However,
for subjects who carry AG or AA genotype for rs10795668,
carrying CT genotypes significantly decreases the disease risk. The
interaction OR can also be calculated from the table. For example,
if there were no interaction effect, samples that carry GG for
rs10795668 and CT for rs367615 would have an increased risk
compared to the reference group (OR would be 1.03*1.11=1.14).
However, they actually have a statistically significantly decreased
Table 1. Studies in Genetics and Epidemiology Colorectal Cancer Consortium (GECCO).
Study Case
{ Control
{ Female Colon Age (yrs)
No. % No. % Mean Range
Phase I N=8,380 N=10,558
ASTERISK 948 947 782 41.3 661 69.7 65.3 40–99
CCFR 1,171 983 1,077 50.0 569 48.6 56.2 19–83
Colo2&3 87 125 95 44.8 59 67.8 65.2 38–86
DACHS I 1,710 1,708 1,395 40.8 1,037 60.6 68.6 33–98
DALS I 706 710 615 43.4 702 99.4 65.0 30–79
MEC 328 346 313 46.4 241 73.5 63.0 45–76
OFCCR
a 650 522 610 52.0 435 66.9 62.1 29–77
PLCO
" 1,019 2,391 1,050 30.8 836 82.0 64.0 55–75
VITAL 285 288 273 47.6 215 75.4 66.5 50–76
WHI 1,476 2,538 4,014 100 1,157 78.4 67.9 50–79
Phase II N=2,527 N=2,658
DACHS II 675 498 440 37.5 375 55.6 69.1 35–99
DALS II 410 464 414 47.4 410 100 65.4 30–79
HPFS 227 230 0 0 158 69.6 66.4 48–82
NHS 553 955 1,508 100 420 75.9 59.8 44–69
PHS 382 389 0 0 296 77.5 59.6 40–85
PMH 280 122 402 100 206 73.6 64.5 50–75
Total=10,907 Total=13,216
Adenoma studies N=826 N=923
HPFS Adv Adnm 313 345 0 0 245* 78.3 60.7 48–81
NHS Adv Adnm 513 578 1,091 100 401* 78.1 57.0 44–69
aSample size excludes overlap with CCFR;
{Sample sizes given only for subjects clustering with HapMap CEU population in PCA (for data that has undergone QC);
"Includes participants with data downloaded from dbGaP prostate and lung studies;*for adenoma, number and % colon does not include subjects with adenomas
located in both colon and rectum.
doi:10.1371/journal.pone.0052535.t001
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23) because of the interaction
(OR=0.76). The interaction OR’s of rs10795668:AG/
rs367615:CT, rs10795668:AG/rs367615:CC, rs10795668:AA/
rs367615:CT and rs10795668:AA/rs367615:CC in Table 3(a)
can easily be calculated to be 0.76, 1.01, 0.60 and 0.89,
respectively. This looks like an unusual interaction pattern.
However, it is worth noting that the sample size is relatively small
when the genotype of rs367615 is CC and as a result, all OR
estimates in the third column have large p-values and wide
confidence intervals. To account for the small sample size, and to
aid interpretation, we re-constructed the interaction table by
combining the CT and CC genotype of rs367615 and the AG and
AA genotypes of rs10795668. Table 3(d) shows that the CT/CC
genotypes of rs367615 have an increased risk when the genotype
of rs10795668 is GG. On the other hand, the combination of AG/
AA genotype of rs10795668 and CT/CC genotype of rs367615
has a protective effect.
As we have fit ARDI and unrestricted model for the top
interaction between rs10795668 and rs367615, it would be
interesting to also see the results from the multiplicative model.
The multiplicative interaction OR is estimated to be 0.83 with
combined p=3.14610
26, which is less significant compared to
ARDI model.
GxG among Top Marginal SNPs
Based on the meta-analysis results of the marginal association
analysis for all except two advanced adenoma studies, we selected
606 SNPs for testing GxG with MAF.0.05, average R
2.0.3, and
both fixed and random effect meta-analysis p,0.0001. Both fixed
and random effect p-values were used because we wanted to avoid
selecting SNPs with signal dominated by a few studies. With this
selection criterion, all chosen SNPs had heterogeneity p-value
.0.1. After applying a LD-pruning routine (Materials and
Methods), 163 SNPs remained.
In Phase I, we observed five pairs of SNPs with fixed-effect
meta-analysis interaction p-value,5610
25 (Table 4). These five
interactions point to 3 independent findings, as indicated by
correlation of the first two SNPs (rs2170568 and rs7006896,
r
2=0.78) and the next two SNPs (rs2200579 and rs10879357,
r
2=0.75). In the replication, the GxG between rs1571218/
20p12.3 and the two correlated SNPs rs2200579 and
rs10879357 which are on 12q21.1 are significant at level 0.1 (p-
values are 0.04 and 0.06, respectively), with interaction ORs in the
same direction. The combined Phase I and II analysis OR and p-
values are 0.81 and 4.61610
26 and 0.80 and 2.51610
26,
respectively. The interaction between rs1571218 and
rs10879357 passed the Bonferroni correction with threshold
3.79610
26=0.05/(163*162/2). After including the two advanced
colorectal adenoma studies, the replication OR and p-value are
0.89 and 0.17 for rs1571218 and rs10879357; the combined
analysis OR and p-value are 0.82 and 1.15610
25. rs1571218 was
well imputed in all studies with average imputation R
2 of 0.95
(range from 0.91 to 0.98); rs10879357 was genotyped in 11 studies
and imputed in 10 studies with average R
2 of 0.78 (range from
0.76 to 0.80). The forest plot shows consistent results across the
individual studies (Figure 3). Again, we did not observe
heterogeneity and random effects results are similar to fixed
effects results.
The two-locus interaction pattern for rs1571218 and
rs10879357 is summarized in Table 5(a). The OR for each SNP
Table 2. Results for selected top interactions for known CRC loci with p-value less than 10
26 in Phase I studies.
Known Locus/region Interacting SNP/region MAF
Phase I Interaction
OR (95% CI) P
Phase II
Interaction
OR (95% CI) P
Combined
Interaction
OR (95% CI) P
Combined
Phet *
rs6687758/1q41 rs9365723/6q25.3 0.43 0.75 (0.67–0.84)
5.83610
27
0.95 (0.77–1.17) 0.63 0.79 (0.71–0.87)
3.79610
26
0.75
rs39453/7p15.3 0.37 0.74 (0.66–0.83)
6.34610
27
0.92 (0.74–1.13) 0.42 0.78 (0.70–0.86)
2.08610
26
0.54
rs17777943/10q24.32 0.10 0.62 (0.51–0.74)
2.77610
27
1.11 (0.80–1.55) 0.53 0.71 (0.60–0.83)
2.81610
25
0.40
rs10795668/10p14 rs367615/5q21.3 0.27 0.74 (0.66–0.84)
8.95610
27
0.76 (0.61–0.95) 0.01 0.74 (0.67–0.83)
4.19610
28
0.39
rs7136702/12q13.13 rs17730929/4q13.2 0.10 0.62(0.51–0.74)
1.72610
27
0.97 (0.68 –1.40) 0.88 0.68 (0.58–0.80)
2.78610
26
0.09
rs751147/14q21.2 0.27 0.73 (0.65–0.82)
8.89610
28
1.16 (0.93–1.45) 0.19 0.80 (0.72–0.89)
3.5610
25
0.13
rs4779584/
15q13/CRAC1
rs10114408/9q22.31 0.24 0.67 (0.58–0.78)
3.26610
27
0.93 (0.71–1.20) 0.56 0.73 (0.64–0.83)
2.54610
26
0.28
rs9929218/16q22.1/CDH1 rs468905/16q21 0.28 0.76 (0.68–0.85)
7.14610
27
1.03 (0.85 –1.26) 0.75 0.82 (0.74–0.90)
2.8610
25
0.36
rs961253/20p12.3/BMP2 rs1661409/11q22.1 0.41 1.36 (1.20–1.54)
9.37610
27
0.97 (0.78–1.20) 0.74 1.25 (1.12–1.39)
4.37610
25
0.05
rs4925386/20q13.33 rs2500295/1p36.32 0.20 1.33 (1.19–1.50)
8.59610
27
0.90 (0.73–1.11) 0.33 1.22 (1.10–1.35)
1.25610
24
0.06
rs4591517/3p24.3 0.28 1.31 (1.18–1.46)
6.92610
27
1.06 (0.88–1.29) 0.54 1.25 (1.14–1.37)
3.26610
26
0.21
rs1394349/18q21.2 0.10 1.51 (1.28–1.78)
8.31610
27
0.98 (0.72–1.34) 0.89 1.38 (1.19–1.59)
1.72610
25
0.08
*Phet is the heterogeneity p-value.
doi:10.1371/journal.pone.0052535.t002
Genome-Wide Search for GxG in Colorectal Cancer
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e52535stratified by the genotypes of the other are summarized in
Table 5(b) and Table 5(c). In Table 5, we can see that all non-
reference combinations are associated with an increased disease
risk compared to the reference group. However, due to
interactions with inverse associations, the risks are not as large
as they would have been without interaction. For example, if there
were no interaction effect, persons who carry AG for rs10879357
and GT for rs1571218 would have an higher risk compared to the
reference group (OR=1.1261.18=1.32). However, the risk is
lower (OR=1.08) because of the interaction (OR=0.82).
Computed as above, the interaction OR’s of rs1571218:GT/
rs10879357:AG, rs1571218:GT/rs10879357:AA, rs1571218:TT/
rs10879357:AG and rs1571218:TT/rs10879357:AA in Table 5(a)
are 0.82, 0.84, 0.83 and 0.89, respectively, which seems to follow a
dominant genetic model. Table 5(b) shows the deleterious
association with allele A of rs10879357 seems to be offset by the
allele T of rs1571218. A similar pattern can also be observed for
rs1571218 in Table 5(c). This indicates that there may be an
exclusive interaction between rs10879357 and rs1571218.
We also calculated the multiplicative interaction OR (=0.94)
and combined p (=0.08) between rs1571218 and rs10879357.
Discussion
In this large study, we performed a genome-wide search for
pairwise GxG for each of the known CRC susceptibility loci and
among top SNPs with small p-values for marginal effects. To our
knowledge, this represents the first comprehensive GxG scan for
colorectal cancer. The most significant interaction found in our
examination of known loci and other SNPs genome-wide was
between the known locus rs10795668 (10p14) and rs367615 (5q21)
with replication p=0.01 and combined p=4.19610
28. The effect
sizes are very similar in Phase I and Phase II studies, and there is
no evidence of heterogeneity (Phet=0.39). Among the top
marginal SNPs, the most promising interaction was between
rs1571218 (20p12.3) and rs10879357 (12q21.1) (nominal
p=2.51610
26; adjusted p=0.03). Again, the effect sizes are very
similar in Phase I and Phase II studies and there is little evidence
for heterogeneity (Phet=0.74).
The known locus rs10795668 in our identified interaction is
located in an intergenic region within 10p14. So far, the function
of this SNP has not been clearly defined and it has not been related
to specific gene(s). The nearest predicted genes in this region are
BC031880 and HV455515 and DD431424, the latter two are
newly identified regulator genes for hTERT, a genetic region that
contains susceptibility loci of multiple different cancers, including
colorectal cancer [9,18–27]. Other genes close by are TAF3 and
GATA3 (,0.6 M bp). GATA3 belongs to the GATA family of
transcription factors, which are important for T-cell development.
TAF3 is a TBP-associated factor (TAF); these contribute to
promoter recognition and selectivity and act as antiapoptotic
factors [28]. rs10795668 has also been found to be correlated with
the expression of ATP5C1 [29], which is involved in cell
metabolism. rs367615 is located in an intergenic region within
Figure 1. Forest plot for meta-analysis results of GxG between rs10795668 and rs367615. Box sizes are proportional to the inverse
variance for each study and the lines depict the confidence intervals. The diamonds represent the fixed effects meta-analysis results, with the widtho f
the diamond representing the confidence interval. The results of two advanced adenoma studies (HPFS Adv Adnm and NHS Adv Adnm) are shown at
the bottom but not incorporated in the meta-analysis.
doi:10.1371/journal.pone.0052535.g001
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(APC) known to be important in both familial and non-familial
colorectal cancer as well as MCC, perhaps also important in CRC
[30,31]. The closest genes to rs367615 are PJA2, MAN2A1 and
FER. PJA2 is responsible for ubiquitination of cAMP-dependent
protein kinase type I and type II-alpha/beta regulatory subunits
and for targeting them for proteasomal degradation [32]. PJA2 has
been found to bind the ubiquitin-conjugating enzyme UbcH5B
[33], which functions in the ubiquitination of the tumor-suppressor
protein p53. FER regulates cell-cell adhesion and mediates
signaling from the cell surface to the cytoskeleton via growth
factor receptors. MAN2A1 is a Golgi enzyme important in N-
glycan processing [34]. Upon additional bioinformatic analysis, we
identified two potential functional candidates, rs2201016 and
rs2201015, that are in strong LD with rs367615 (r
2 values of 1 and
0.916 respectively). As shown in the UCSC Genome Browser view
(Figure S2, Table S2), rs2201016 and rs2201015 fall within a
region of strong DNAse hypersensitivity and evolutionary conser-
vation. As shown in Table 3(a), the interaction seems to be driven
by the CT group of rs367615, which is an uncommon
phenomenon and may be related to heterozygote advantage.
However, the minor allele heterozygous (CC) genotype is relatively
rare, making it difficult to conclusively estimate the effect size in
that genotyped. Although both SNPs point to potentially relevant
genes involved in cancer development, advancing basic research
and translating these GWAS findings in to clinical benefit will
require further functional characterization through in vitro and
in vivo analysis.
We observed a statistically significant interaction between
rs1571218/20p12.3 and rs10879357/12q21.1 (and a marginally
significant interaction with a close by and correlated SNP,
rs2200579). The SNP rs1571218 is in the same region (20p12.3)
and modestly correlated (r
2=0.56) with the known CRC locus
rs961253. The closest gene is bone morphogenetic protein 2
(BMP2), which is part of transforming growth factor-beta (TGF-b)
pathway. The TGF-b pathway plays an important role in cell
proliferation, differentiation, and apoptosis [35] and is established
as important in CRC [36]. Two interacting SNPs rs2200579 and
rs10879357 are close together (,4 k bp apart) at 12q21.1 and are
correlated (r
2=0.76). These SNPs fall in the intronic region of
TPH2, which is a rate-limiting enzyme in the synthesis of serotonin
[37]. Serotonin is known to be involved in numerous central
nervous activities. There is also evidence that serotonin is
mitogenic in different cancer cell lines [38–40]. One study has
shown that lack of serotonin causes a reduction of tumor growth in
a mouse model of colon cancer allografts [41]. Further bioinfor-
matic analysis revealed that rs10879357 is in LD (r2=0.697) with
a synonymous coding SNP (rs4290270) in the exonic region
towards the tail end of TPH2. Further in vivo or in vitro analysis is
necessary to determine whether this variant has a functional
impact such as mRNA stability. Because rs2200579 and
rs10879357 are in a gene rich region, it is also possible that the
SNPs impact genes other than TPH2.
Figure 2. Regional interaction association plot for interacting region 5q21 with known CRC locus rs10795668. The left y-axis shows the
-log10 of the meta-analysis interaction p value. The right y-axis shows the recombination rate. Each dot on the plot represents the result for one SNP.
The diamond dot represents SNP rs367615 and the round dots represent other SNPs. Difference colors of SNPs indicate different LD strength
between the corresponding SNP and rs367615, measured by r
2. The bottom of the figure shows the genes in the plotted region.
doi:10.1371/journal.pone.0052535.g002
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to the time their genotype data became available. Phase II was
expected to serve as validation/replication of Phase I. For the
known loci GxG search, the Phase II p-value between rs10795668
and rs367615 is 0.01, which is nominally significant at the 0.05
level but does not pass the Bonferroni threshold (0.05/12). Among
the top marginal SNPs, the Phase II p-value between rs1571218
and rs10879357 also does not pass the Bonferroni threshold (0.05/
5) even when the combined p-value passes the Bonferroni
threshold (3.79610
26=0.05/(163*162/2)). In fact, combined test
was recommended in two-stage GWAS because the replication test
has been shown to be less efficient compared to combined test
[42]. Therefore, larger sample size is needed to reach enough
power to replicate our findings.
Adenomas are well known precursor lesions of colorectal
cancer. Accordingly, we investigated if the observed interactions
for colorectal cancer are also seen in advanced colorectal
adenomas. Our findings suggest that the interaction between
rs10795668 and rs367615 is present in advanced adenomas,
suggesting that the genetic variants may act early in the
development of colorectal cancer. In contrast, the interaction
between rs1571218 and rs10879357 was not observed in advanced
adenoma, which may suggest that the genetic variants act at a later
stage of cancer development. However, the findings need to be
interpreted with caution, as the number of adenomas is relatively
small (,1000 cases).
In marginal association analysis, the most commonly used
model is the log-additive model, where the genotype is coded as 0,
1 or 2 (based on the number of count alleles). It is therefore natural
to use the same genetic coding in a two-locus interaction model to
test for GxG. In the interaction model, the interaction effect is
modeled by the product of the genotypes of two SNPs. As we can
see in Table 6(a), this interaction model assumes that the
interaction when both SNPs have homozygous genotype (=2) is
four times as large as when both SNPs have heterozygous
genotype (=1). In other words, this model assumes b22~4b11 in
the Table 6(b), which is a strong assumption. Indeed, we can see
that the interaction pattern in Table 3(a) is not consistent
with this assumption. Some simple calculations demonstrate
thatb22 =log(0.89), which actually represents a smaller effect size
compared to b11 =log(0.76). In fact, we have found in simulation
that violation of this assumption can result in substantial loss of
power (Figure S1). A cautious way to avoid posing such a strong
assumption is to use an unrestricted model, which is also a widely
adopted method [17,43]. Using an unrestricted model can avoid
violation of assumptions but may result in substantial loss of power
because of the increased degrees of freedom (from 1 to 4). Our
ADRI method uses the same genetic coding as the log-additive
Table 3. Interaction pattern between rs10795668 and rs367615.
Table 3(a).
rs367615:TT rs367615:CT rs367615:CC
rs10795668:GG 1 1.11 (1.02–1.22) 1.73610
22 1.07 (0.87–1.32) 5.18610
21
3212/3968 1599/1783 229/246
rs10795668:AG 1.03 (0.95–1.10) 5.00610
21 0.87 (0.80–0.95) 2.99610
23 1.12 (0.92–1.36) 2.50610
21
2896/3585 1355/1858 349/316
rs10795668:AA 1.14 (1.01–1.30) 3.19610
22 0.76 (0.64–0.89) 9.35610
24 1.10 (0.85–1.42) 4.52610
21
691/771 319/493 250/193
For each combination of genotypes, we computed the odds ratio (95% CI), and pvalue relative to the baseline group (rs10795668:GG; rs367615:TT). We also list the
sample size for cases/controls.
Table 3(b). OR of rs367615 stratified by rs10795668
rs367615:TT rs367615:CT rs367615:CC
rs10795668:GG 1 1.11 (1.02–1.22) 1.73610
22 1.07 (0.87–1.32) 5.18610
21
rs10795668:AG 1 0.85 (0.78–0.93) 5.82610
24 1.09 (0.90–1.33) 3.70610
21
rs10795668:AA 1 0.66 (0.55–0.80) 2.96610
25 0.96 (0.73–1.27) 7.88610
21
Table 3(c). OR of rs107895668 stratified by rs367615
rs367615:TT rs367615:CT rs367615:CC
rs10795668:GG 1 1 1
rs10795668:AG 1.03 (0.95–1.10) 5.00610
21 0.78 (0.70–0.87) 5.27610
26 1.05 (0.80–1.37) 7.43610
21
rs10795668:AA 1.14 (1.01–1.30) 3.19610
22 0.68 (0.57–0.81) 1.17610
25 1.03 (0.76–1.40) 8.58610
21
Table 3(d). Interaction pattern between rs10795668 and rs367615 by combining the heterozygous and homozygous minor genotypes.
rs367615:TT rs367615:CT/CC
rs10795668:GG 1 1.11 (1.02–1.20) 1.96610
22
rs10795668:AG/AA 1.05 (0.98–1.12) 1.92610
21 0.88 (0.81–0.95) 1.67610
23
doi:10.1371/journal.pone.0052535.t003
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interaction test independent of the marginal screening. For the
interaction, our method estimates the average interaction effect   b b
of b11, b12, b21, and b22. Because   b b is an average effect, it is less
prone to heterogeneity among studies. As a result, our method is
more stable and reproducible compared to the unrestricted and
log-additive model. It is worth pointing out that when the
underlying genetic model is indeed log-additive, ARDI is less
powerful compared to the regular interaction model with log-
additive genetic coding. For future applications, a model selection
technique needs to be developed to determine the most
appropriate model with the least loss of power. Another worth
noting point is that the case-only model, which assumes
independence between SNPs in controls, is known to be more
powerful than the case control combined model while testing for
gene-gene interaction [44,45]. In our case, ARDI is a case control
combined approach so the power can also be boosted by using its
case-only counterpart. We did not implement the case-only ARDI
for two reasons: it is relatively hard to completely avoid violation of
the independence assumption (thus maintain the type I error rate)
in case-only model due to the complexity of the LD structure of
the human genome, i.e, long-range LD [46]; in addition, the
Figure 3. Forest plot for meta-analysis results of GxG between rs1571218 and rs10879357. Box sizes are proportional to the inverse
variance for each study and the lines depict the confidence intervals. The diamonds represent the fixed effects meta-analysis results, with the widtho f
the diamond representing the confidence interval. The results of two advanced adenoma studies (HPFS Adv Adnm and NHS Adv Adnm) are shown at
the bottom but not incorporated in the meta-analysis.
doi:10.1371/journal.pone.0052535.g003
Table 4. Results for selected top interactions among top marginal loci with p-value less than 5610
25 in Phase I studies.
Interacting SNP
1/region MAF 1 Interacting SNP 2/region MAF 2
Phase I Interaction
OR(95% CI) P
Phase II
Interaction
OR(95% CI) P
Combined
Interaction
OR(95% CI) P
Combined
Phet
rs11106204/12q21.33 0.21 rs2170568/8q24.21 0.17 1.38 (1.19–1.60)
1.33610
25
0.97 (0.75–1.26)
0.82
1.27 (1.12–1.44)
2.24610
24
0.02
rs7006896/8q24.21 0.17 1.38 (1.19–1.59)
1.29610
25
0.97 (0.75–1.26)
0.82
1.27 (1.12–1.44)
2.16610
24
0.03
rs1571218/20p12.3 0.48 rs2200579/12q21.1 0.31 0.81 (0.73–0.89)
4.72610
25
0.81 (0.67–0.99)
0.04
0.81 (0.74–0.89)
4.61610
26
0.77
rs10879357/12q21.1 0.38 0.79 (0.70–0.88)
1.37610
25
0.83 (0.69–1.01)
0.06
0.80 (0.72–0.88)
2.51610
26
0.74
rs4766549/12q24.11 0.16 rs10879357/12q21.1 0.38 0.73 (0.63–0.85)
3.03610
25
0.90 (0.70–1.17)
0.43
0.77 (0.68–0.88)
6.3610
25
0.71
Phet is the heterogeneity p-value.
doi:10.1371/journal.pone.0052535.t004
Genome-Wide Search for GxG in Colorectal Cancer
PLOS ONE | www.plosone.org 8 December 2012 | Volume 7 | Issue 12 | e52535current available package [47] for fitting a case-only model with
covariates are only applicable to genotyped SNPs while our data
include imputed dosages. As an on-going work, we are developing
a package that can fit case-only model for two imputed SNPs while
adjusting for covariates.
GxG is usually defined as the departure from main effects [13].
Therefore, if the underlying main effects are not correctly
specified, the residual main effects could be incorporated as part
of the interaction effect in the statistical model [48]. As a result,
testing interaction implicitly evaluates the residual main effect and
interaction effect jointly. We keep the main effects as log-additive
in ARDI, mainly because we want to be consistent with the usual
log-additive model used in the marginal association analysis so that
ARDI test is independent of the marginal screening. However, the
log-additive main effect is prone to model misspecification. We
observed this in our study for four of the known loci, rs10936599,
rs6983267, rs4779584 and rs961253. These SNPs all showed an
inflated lfor the interaction tests when using additive genetic
coding for the main effect. In all four cases, the inflation
ldiminished after we switched to unrestricted coding with no
misspecification. VanderWeele and Laird (2011) used a similar
approach to protect against potential misspecification of main
effects [49]. We tried ARDI with unrestricted main effect on our
top findings. Under the ARDI model with unrestricted main
effect, the interaction between known locus rs10795668 and
rs367615 has an OR of 0.75 and combined p=1.07610
26
(original OR=0.74 and combined p=4.19610
28); interaction
between rs1571218 and rs10879357 has an OR of 0.83 and
combined p=3.90610
24 (original OR=0.80 and combined
p=2.51610
26). As we can see, the OR’s stay largely the same
and there are still strong signals of interaction. However, the p-
values get larger in the new model, which could be due to random
fluctuations between different models, or also could be a sign of
main effect misspecification. Hence, our interaction test results
should be interpreted with caution.
In our GxG search, we performed genome-wide interaction
search for each known CRC locus and all other SNPs, including
the SNPs that are in LD with it. This raises an important concern
whether it is appropriate to test GxG between two SNPs that are
in high LD. As an alternative, it is of interest to conduct haplotype
analysis on the nearby regions of the known loci. We also
prioritized SNPs based on their marginal association strength,
using established methods [50]. Our reasoning is that if a SNP is
involved in GxG, it is also likely that it will show evidence of some
marginal effect. As most SNPs in GWAS are null, selecting a
subset of SNPs that are more likely to show interaction could
increase the power substantially as it reduces the overall multiple
comparison burden. However, it is also possible for a SNP to show
little or no marginal association if it is involved in interaction that
is in the opposite direction to that seen with the main effect. In this
case, we would not be able to find those qualitative interactions
using our screening. Future research is needed to explore methods
to complement the marginal association screening while still
restricting the number of tests at a reasonable level to ensure
reasonable power.
In this paper, we focused on pair-wise interactions. For higher
order interactions, data mining methods such Random Forest
[51,52] and Multifactor Dimensionality Reduction [53] are
preferred compared to the traditional regression-based methods
because of the scarcity of the potential high-order contingency
Table 5. Interaction pattern between rs1571218 and rs10879357.
Table 5(a)
rs10879357:GG rs10879357:AG rs10879357:AA
rs1571218:GG 1 1.12 (1.00–1.25) 4.96610
22 1.36 (1.18–1.57) 2.22610
25
1383/1918 1930/2457 729/781
rs1571218:GT 1.18 (1.06–1.31) 3.31610
23 1.08 (0.98–1.20) 1.32610
21 1.35 (1.18–1.54) 1.03610
25
1781/2186 2384/3022 948/1008
rs1571218:TT 1.35 (1.16–1.57) 9.59610
25 1.25 (1.09–1.44) 1.35610
23 1.63 (1.33–2.00) 2.20610
26
599/649 787/885 345/308
For each combination of genotypes, we computed the odds ratio (95% CI) and pvalue relative to the baseline group (rs1571218:GG; rs10879357:GG). We also list the
sample size for cases/controls.
Table 5(b). OR of rs10879357 stratified by rs1571218
rs10879357:GG rs10879357:AG rs10879357:AA
rs1571218:GG 1 1.12 (1.00–1.25) 4.96610
22 1.36 (1.18–1.57) 2.22610
25
rs1571218:GT 1 0.92 (0.83–1.01) 8.81610
22 1.14 (1.01–1.30) 4.05610
22
rs1571218:TT 1 0.93 (0.78–1.11) 4.10610
21 1.21 (0.96–1.51) 1.03610
21
Table 5(c). OR of rs 1571218 stratified by rs10879357
rs10879357:GG rs10879357:AG rs10879357:AA
rs1571218:GG 1 1 1
rs1571218:GT 1.18 (1.06–1.31) 3.31610
23 0.97 (0.88–1.07) 5.06610
21 0.99 (0.84–1.16) 8.85610
21
rs1571218:TT 1.35 (1.16–1.57) 9.59610
25 1.12 (0.98–1.28) 8.69610
22 1.20 (0.96–1.49) 1.12610
21
doi:10.1371/journal.pone.0052535.t005
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data mining methods, except for Random Forest, are computa-
tionally intensive, and hence, are not easily applicable to GWAS
data. In addition, as the data mining methods are nonparametric,
permutation tests are usually needed to produce p-value.
Unfortunately they are generally computationally impossible for
GWAS. Given the aforementioned limitations, one possible
practical approach for searching for higher order GxG is to use
Random Forest in a discovery dataset and use traditional
regression-based methods to replicate the findings.
It is important to note that we focused on testing statistical
interaction in this paper and statistical interaction does not always
warrant a biologic or mechanistic interaction [54]. Mechanistic
interaction can be tested using the sufficient cause framework [55],
which is out of the scope of this paper.
In summary, our study is the first to comprehensively search for
GxG for CRC. We have found evidence for two interactions
associated with CRC risk. Further studies are needed to evaluate
these interactions and to study the underlying molecular mech-
anisms.
Materials and Methods
Study Participants
The studies used in this analysis, including number of cases and
controls, are listed in Table 1, with each study described in detail
in the Text S1. In brief, colorectal cancer cases were defined as
adenocarcinoma of colon and rectum (International Classification
of Disease Code 153–154) and were confirmed by medical record,
pathology report, or death certificate. Advanced colorectal
adenoma cases are defined as adenoma $1 cm in diameter
and/or with tubulovillous, villous, or high-grade dysplasia/
carcinoma-in-situ histology, and were confirmed by medical
record, histopathology, or pathology report. All participants
provided written informed consent and studies were approved
by the Institutional Review Board.
Genotyping
We conducted genome-wide scans for all studies. GECCO
GWAS consisted of participants of European ancestry within 13
studies including the French Association Study Evaluating RISK
for sporadic colorectal cancer (ASTERISK); Hawaii Colorectal
Cancer Studies 2 and 3 (Colo2&3); Darmkrebs: Chancen der
Verhutung durch Screening (DACHS); Diet, Activity, and
Lifestyle Study (DALS); Health Professionals Follow-up Study
(HPFS); Multiethnic Cohort (MEC); Nurses’ Health Study (NHS);
Ontario Familial Colorectal Cancer Registry (OFCCR); Physi-
cian’s Health Study (PHS); Postmenopausal Hormone study
(PMH); Prostate, Lung, Colorectal Cancer, and Ovarian Cancer
Screening Trial (PLCO); VITamins And Lifestyle (VITAL); and
the Women’s Health Initiative (WHI). Phase one genotyping on a
total of 1,709 colon cancer cases and 4,214 controls from PLCO,
WHI, and DALS (PLCO Set 1, WHI Set 1, and DALS Set 1) was
done using Illumina Human Hap 550 K, 610 K, or combined
Illumina 300 K and 240 K, and has been described previously [9].
A total of 650 colorectal cancer cases and 522 controls from
OFCCR are included in GECCO from previous genotyping using
Affymetrix platforms [2]. A total of 5,540 colorectal cancer cases
and 5,425 controls from ASTERISK, Colo2&3, DACHS Set 1,
DALS Set 2, MEC, PMH, PLCO Set 2, VITAL, and WHI Set 2
were successfully genotyped using Illumina HumanCytoSNP. A
total of 1,837 colorectal cancer cases and 2,072 controls from
HPFS, NHS, PHS, and DACHS set 2, as well as a total of 826
advanced adenoma cases and 923 controls from HPFS and NHS
were successfully genotyped using Illumina HumanOmniExpress.
A population-based case-control GWAS from CCFR (1,171 cases
and 983 controls) was successfully genotyped using Illumina
Human1M or Human1M-Duo [56].
We divided the studies into two phases according to the time
their genotype data became available (Table 1). We used the Phase
I studies (10 studies; 8,380 cases and 10,558 controls) as the
discovery set and Phase II studies (6 studies; 2,527 cases and 2,628
controls) as the replication set. In addition, there are two advanced
colorectal adenoma studies, which we use to evaluate whether the
interactions found for carcinoma are also associated with
advanced adenoma.
DNA was extracted from blood samples or, in the case of a
subset of DACHS, MEC, and PLCO samples, and all VITAL
samples, from buccal cells using conventional methods. All studies
included 1 to 6% blinded duplicates to monitor quality of the
genotyping. All individual-level genotype data were managed
centrally at University of Southern California (CCFR), the
Ontario Institute for Cancer Research (OFCCR), the University
of Washington (HPFS, NHS, PHS, and the second GWAS of
DACHS), or the GECCO Coordinating Center at the Fred
Hutchinson Cancer Research Center (all other studies) to ensure a
consistent quality assurance and quality control approach and
statistical analysis. Samples were excluded based on call rate,
heterozygosity, unexpected duplicates, gender discrepancy, and
unexpectedly high identity-by-descent or unexpected concordance
(.65%) with another individual. All analyses were restricted to
samples clustering with the CEU population in principal
component analysis, including the three HapMap populations as
Table 6. An illustration of different two-SNP interaction
models. SNP 1 has genotype AA, Aa and aa; SNP 2 has
genotype BB, Bb, and bb. A and B are the major alleles for
SNP1 and 2, respectively.
(a)
AA Aa aa
BB 1 R01 R2
01
Bb R10 R01R10eb R2
01R10e2b
bb R2
10 R01R2
10e2b R2
01R2
10e4b
(b)
AA Aa aa
BB 1 R01 R02
Bb R10 R01R10eb11 R02R10eb12
bb R20 R01R20eb21 R02R20eb22
(c)
AA Aa aa
BB 1 R01 R2
01
Bb R10 R01R10e
  b b R2
01R10e
  b b
bb R2
10 R01R2
10e
  b b R2
01R2
10e
  b b
Each entry in the tables represents the risk of the corresponding genotype
combination relative to the baseline (AA/BB). (a) Multiplicative interaction
model; (b) Unrestricted interaction model; (c) Average Risk Due to Interaction
(ARDI) model.
doi:10.1371/journal.pone.0052535.t006
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assigned an rs number, or were reported as not performing
consistently across platforms. Additionally, they were excluded
based on call rate (,98%), Hardy Weinberg Equilibrium in
controls (HWE, p,10
24), and minor allele frequency. To place
studies on a common set of autosomal SNPs, all studies were
imputed to HapMap II release 24, with the exception of OFCCR,
which was imputed to HapMap II release 22. CCFR was imputed
using IMPUTE [57], OFCCR was imputed using BEAGLE [58],
and all other studies were imputed using MACH [59]. Given the
high agreement of imputation accuracy among MACH, IM-
PUTE, and BEAGLE [60] the common practice to use different
imputation programs is unlikely to cause heterogeneity [61].
Imputed data were merged with genotype data such that genotype
data were preferentially selected if a SNP had both types of data,
unless there was a difference in terms of reference allele frequency
(.0.1) or position (.100 base pairs), in which case imputed data
were used. As a measurement of imputation accuracy, we
calculated R
2 [59].
For the GxG analysis, we restricted the search to SNPs with
MAF.0.05 and imputation R
2.0.3 because there is inadequate
power to detect interactions between less frequent variants or
variants with lower imputation quality given the current sample
size.
Statistical Method
GxG model. A logistic regression model was used to assess
GxG for each SNP pair tested. In particular, we used a simple yet
powerful approach named ‘‘Average Risk Due to Interaction
(ARDI)’’ to test for GxG. In this approach, the main effects of the
SNPs are log-additive and the interaction effect is the averaged
deviation from the main effects. This is in contrast to the usual
modeling of the interaction effect for log-additive model, where
the interaction term is the product of the two SNPs. To see this, we
consider two SNPs, G1 (=AA, Aa or aa) and G2 (=BB, Bb, or bb)
while A and B are the major alleles for G1 and G2, respectively.
Table 6(a) shows the usual interaction model with log-additive
effects. Under this model, the interaction effect of aa/bb
combination relative to the main effects is exp(4b), which is
considerably larger than the Aa/Bb combination, which is exp(b).
One way to avoid this strong assumption of interaction pattern is
to use an unrestricted model (Table 6(b)), which models the
interaction effect by four parameters b11, b12, b21, and b22. A four-
degrees-of-freedom test is needed to test for the interaction effect,
which may result in a substantial power loss. We therefore
modeled the average interaction effect with one parameter   b b while
keeping the main effect as log-additive (ARDI) (see Table 6(c)).
This modeling avoids the strong assumption of the usual modeling
of interactions with log-additive main effects, and yet gains power
by having only one parameter to test for interaction. We keep the
main effects as log-additive, mainly because we want to be
consistent with the usual log-additive model used in the marginal
association analysis. We have conducted extensive simulation
studies to compare the performance of ARDI with multiplicative
interaction model and unrestricted interaction model. Simulation
results show that ARDI has favorable performance while the
underlying interaction pattern is unknown (see Text S1, Table S1
and Figure S1). We have also tried both multiplicative model and
ARDI in the Phase I studies and ARDI yielded more significant
results genome widely, which supported the conclusion from the
simulation because in this case the true underlying interaction is
unknown and likely to vary among SNPs. Hence, we chose ARDI
as our GxG model. Specifically, the ARDI model can be written
as:
logit(d)~a0za1fI(G1~Aa)z2I(G1~aa)g
za2fI(G2~Bb)z2I(G2~bb)g
z  b bfI(G1~Aa)I(G2~Bb)
zI(G1~aa)I(G2~Bb)zI(G1~Aa)I(G2~bb)
zI(G1~aa)I(G2~bb)gzcovariates,
where d is the disease status (0/1), a0 is the intercept, a1 and a2 are
the main effects,   b b is the ARDI interaction effect. The hypothesis
is to test whether   b b~0. For all models, we adjusted for age, sex,
study center, and the first three principal components from
EIGENSTRAT [62] to account for population substructure.
GxG searching strategy. We performed genome-wide
interaction testing for each of the 14 known CRC susceptibility
loci and all other 2.1 M SNPs in the Phase I studies. SNPs with
p,10
26 in Phase I were examined in the Phase II studies using the
same ARDI model.
We also conducted a genome-wide search of GxG for all SNPs,
using a two-stage approach. In the first stage, we did a genome-
wide marginal association test with additive genetic coding for all
2.1 M SNPs. Then we selected SNPs with marginal association p-
value ,0.0001 for the second stage and searched for pair-wise
interactions among the selected SNPs. We selected 0.0001 as the
cutoff so that around 100 independent regions would be selected
assuming there are one million independent regions genome-wide
[63]. It has been shown that the screening on marginal association
is independent of the GxG test as long as the genetic coding for the
main effect is the same as in the marginal association testing [50].
Because both the marginal association test and the main effect of
ARDI use additive genetic coding, we need to adjust only for the
number of interaction tests performed in the second stage to
maintain the correct type I error level.
We observed 606 SNPs with marginal association p,0.0001.
However, the 606 selected SNPs are not independent due to
linkage disequilibrium (LD) between SNPs. As a result, if we used
the number of pair-wise interactions among those 606 SNPs
(n=183,315) with a Bonferroni correction to compute the
adjusted alpha level, the result would be too conservative.
Therefore, we performed a pruning based on LD. First, the
selected SNPs were ranked based on the marginal association p-
value. Starting with the first SNP (SNP with the strongest signal),
we removed all SNPs that have a LD r
2.0.8 with that SNP. Then
we moved to the next SNP, and repeated the procedure until we
reached the end of the list. A total of 163 SNPs remained after this
LD pruning. We then tested for GxG among these SNPs in Phase
I studies. Interactions with p,5610
25 were selected for Phase II
(so the expected number of false positive based on total 163*162/
2=13,203 interaction tests is less than one).
Meta-analysis
We used the fixed-effect meta-analysis to combine interaction
estimates across studies. In this approach, we used the inverse-
variance weighting to combine the regression coefficient estimates
from each study. As previously demonstrated [64], the imputation
quality is automatically incorporated into meta-analysis with the
inverse-variance weighting. We report the summary estimate,
standard error, and 95% confidence interval, as well as the
heterogeneity p-value for the meta-analysis. For top findings we
examined whether a random effects model would result in
substantively different results from our fixed effects model. We
Genome-Wide Search for GxG in Colorectal Cancer
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meta-analysis results for Phase I alone, Phase II alone, and Phase I
and II combined.
Genomic Inflation
We checked the QQ plot and genomic inflation factor l for the
GxG meta-analysis results of each known locus. Among 14 known
loci, 10 of them showed no systematic bias, with l ‘s less than 1.05.
However, rs10936599, rs6983267, rs4779584 and rs961253
showed some indication of an inflated l (1.10–1.78). For each of
these SNPs we found that the systematic inflation was due to
inappropriate additive genetic coding for the main effect. If the
main effect for a SNP does not follow an additive model (with the
heterozygote effect half way between the two homozygotes on the
log scale), but additive coding is used, this misspecification results
in a residual main effect. The residual effect impacts the testing for
the interaction and causes the inflation (see Discussion for more
details). For those four SNPs, we switched their main effect coding
from an additive model to a 2 degree of freedom unrestricted
coding and observed that the inflation factor for the interaction
GxG meta-analysis results was diminished (l#1.01).
Supporting Information
Figure S1 Simulation results comparing the perfor-
mance of ARDI (red bars), multiplicative interaction
model (black bars), and unrestricted interaction model
(blue bars). For each model, the barplots show the power (type I
error for Model 1) of each method under different parameter
settings.
(DOCX)
Figure S2 ENCODE Integrated Regulation Tracks for
5q21.
(DOCX)
Table S1 An illustration of six two-SNP interaction
models used in the simulation. SNP 1 has genotype AA,
Aa and aa; SNP 2 has genotype BB, Bb, and bb. A and B are the
major alleles for SNP1 and 2, respectively. Each entry in the tables
represents the risk of the corresponding genotype combination.
(DOCX)
Table S2 Tools for functional annotation of non-coding
variants.
(DOCX)
Text S1
(DOCX)
Acknowledgments
We thank the reviewers for their helpful comments.
ASTERISK: We are very grateful to Dr. Bruno Buecher without whom
this project would not have existed. We also thank all those who agreed to
participate in this study, including the patients and the healthy control
persons, as well as all the physicians, technicians and students.
DACHS: We thank all participants and cooperating clinicians, and Ute
Handte-Daub, Renate Hettler-Jensen, Utz Benscheid, Muhabbet Celik
and Ursula Eilber for excellent technical assistance.
GECCO: The authors would like to thank all those at the GECCO
Coordinating Center for helping bring together the data and the people
that made this project possible.
HPFS, NHS, PHS: We would like to acknowledge Patrice Soule and
Hardeep Ranu of the Dana Farber Harvard Cancer Center High-
Throughput Polymorphism Core who assisted in the genotyping for NHS,
HPFS, and PHS under the supervision of Dr. Immaculata Devivo and Dr.
David Hunter, Qin (Carolyn) Guo and Lixue Zhu who assisted in
programming for NHS and HPFS, and Haiyan Zhang who assisted in
programming for the PHS. We would like to thank the participants and
staff of the Nurses’ Health Study and the Health Professionals Follow-Up
Study, for their valuable contributions as well as the following state cancer
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL,
IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH,
OK, OR, PA, RI, SC, TN, TX, VA,WA, WY.
PLCO: The authors thank Drs. Christine Berg and Philip Prorok,
Division of Cancer Prevention, National Cancer Institute, the Screening
Center investigators and staff or the Prostate, Lung, Colorectal, and
Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff,
Information Management Services, Inc., Ms. Barbara O’Brien and staff,
Westat, Inc., and Drs. Bill Kopp, Wen Shao, and staff, SAIC-Frederick.
Most importantly, we acknowledge the study participants for their
contributions to making this study possible.
PMH: The authors would like to thank the study participants and staff
of the Hormones and Colon Cancer study.
WHI: The authors thank the WHI investigators and staff for their
dedication, and the study participants for making the program possible.
A full listing of WHI investigators can be found at: https://cleo.
whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%
20Investigator%20Short%20List.pdf.
Author Contributions
Conceived and designed the experiments: SJ LH SB SB HB DB BJC CSC
GC ATC JC SC DVC DD SG SBG RBH BEH MH JLH TJH CMH RDJ
MAJ LNK SK LL ML PAN JDP RES FRS DS MLS CMU BWZ UP.
Performed the experiments: SJ LH SB SB HB DB BJC CSC GC ATC JC
SC DVC KRC DD SG SBG TAH RBH BEH MH JLH TJH CMH RDJ
MAJ EDK LNK SK LL ML PAN JDP CQ RES FRS DS MLS CMU
BWZ UP. Analyzed the data: SJ LH KRC CMH CQ. Contributed
reagents/materials/analysis tools: SJ LH CMH CQ UP SAR KRC PTC.
Wrote the paper: SJ LH CMH UP SAR MAJ ML EDK JDP CMU.
References
1. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, et al. (2007)
A genome-wide association scan of tag SNPs identifies a susceptibility variant for
colorectal cancer at 8q24.21. Nature genetics 39: 984–988. doi:10.1038/ng2085.
2. Zanke BW, Greenwood CMT, Rangrej J, Kustra R, Tenesa A, et al. (2007)
Genome-wide association scan identifies a colorectal cancer susceptibility locus
on chromosome 8q24. Nature genetics 39: 989–994. doi:10.1038/ng2089.
3. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, et al.
(2007) A genome-wide association study shows that common alleles of SMAD7
influence colorectal cancer risk. Nature genetics 39: 1315–1317. doi:10.1038/
ng.2007.18.
4. Tenesa A, Farrington SM, Prendergast JGD, Porteous ME, Walker M, et al.
(2008) Genome-wide association scan identifies a colorectal cancer susceptibility
locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nature genetics 40:
631–637. doi:10.1038/ng.133.
5. Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, et al. (2008)
Common genetic variants at the CRAC1 (HMPS) locus on chromosome
15q13.3 influence colorectal cancer risk. Nature genetics 40: 26–28.
doi:10.1038/ng.2007.41.
6. Tomlinson IPM, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, et al.
(2008) A genome-wide association study identifies colorectal cancer susceptibility
loci on chromosomes 10p14 and 8q23.3. Nature genetics 40: 623–630.
doi:10.1038/ng.111.
7. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, et al. (2008)
Meta-analysis of genome-wide association data identifies four new susceptibility
loci for colorectal cancer. Nature genetics 40: 1426–1435. doi:10.1038/ng.262.
8. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, et al. (2010) Meta-
analysis of three genome-wide association studies identifies susceptibility loci for
colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature genetics 42:
973–977. doi:10.1038/ng.670.
9. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, et al. (2011) Meta-
analysis of new genome-wide association studies of colorectal cancer risk.
Human genetics. doi:10.1007/s00439–011–1055–0.
10. Tomlinson IPM, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, et
al. (2011) Multiple Common Susceptibility Variants near BMP Pathway Loci
GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of
Colorectal Cancer. PLoS genetics 7: e1002105. doi:10.1371/journal.p-
gen.1002105.
Genome-Wide Search for GxG in Colorectal Cancer
PLOS ONE | www.plosone.org 12 December 2012 | Volume 7 | Issue 12 | e5253511. Culverhouse R, Suarez BK, Lin J, Reich T (2002) A perspective on epistasis:
limits of models displaying no main effect. American journal of human genetics
70: 461–471. doi:10.1086/338759.
12. Moore JH (2003) The ubiquitous nature of epistasis in determining susceptibility
to common human diseases. Human heredity 56: 73–82. doi:10.1159/
000073735.
13. Cordell HJ (2009) Detecting gene-gene interactions that underlie human
diseases. Nature reviews Genetics 10: 392–404. doi:10.1038/nrg2579.
14. Van Steen K (2011) Travelling the world of gene-gene interactions. Briefings in
bioinformatics: bbr012–. doi:10.1093/bib/bbr012.
15. Zuk O, Hechter E, Sunyaev SR, Lander ES (2012) The mystery of missing
heritability: Genetic interactions create phantom heritability. Proceedings of the
National Academy of Sciences of the United States of America 109: 1193–1198.
doi:10.1073/pnas.1119675109.
16. Strange A, Capon F, Spencer CCA, Knight J, Weale ME, et al. (2010) A
genome-wide association study identifies new psoriasis susceptibility loci and an
interaction between HLA-C and ERAP1. Nature genetics 42: 985–990.
doi:10.1038/ng.694.
17. Liu Y, Xu H, Chen S, Chen X, Zhang Z, et al. (2011) Genome-wide interaction-
based association analysis identified multiple new susceptibility Loci for common
diseases. PLoS genetics 7: e1001338. doi:10.1371/journal.pgen.1001338.
18. Hsiung CA, Lan Q, Hong Y-C, Chen C-J, Hosgood HD, et al. (2010) The
5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking
females in Asia. PLoS genetics 6. doi:10.1371/journal.pgen.1001051.
19. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, et al. (2009) A
genome-wide association study of lung cancer identifies a region of chromosome
5p15 associated with risk for adenocarcinoma. American journal of human
genetics 85: 679–691. doi:10.1016/j.ajhg.2009.09.012.
20. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, et al. (2008) Lung
cancer susceptibility locus at 5p15.33. Nature genetics 40: 1404–1406.
doi:10.1038/ng.254.
21. Miki D, Kubo M, Takahashi A, Yoon K-A, Kim J, et al. (2010) Variation in
TP63 is associated with lung adenocarcinoma susceptibility in Japanese and
Korean populations. Nature genetics 42: 893–896. doi:10.1038/ng.667.
22. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, et
al. (2010) A genome-wide association study identifies pancreatic cancer
susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature
genetics 42: 224–228. doi:10.1038/ng.522.
23. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, et al. (2009) Sequence
variants at the TERT-CLPTM1L locus associate with many cancer types.
Nature genetics 41: 221–227. doi:10.1038/ng.296.
24. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. (2009)
Genome-wide association study identifies five susceptibility loci for glioma.
Nature genetics 41: 899–904. doi:10.1038/ng.407.
25. Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, et al. (2009)
New common variants affecting susceptibility to basal cell carcinoma. Nature
genetics 41: 909–914. doi:10.1038/ng.412.
26. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, et al. (2010) Variants near
DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer.
Nature genetics 42: 604–607. doi:10.1038/ng.607.
27. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, et al. (2008) Common
5p15.33 and 6p21.33 variants influence lung cancer risk. Nature genetics 40:
1407–1409. doi:10.1038/ng.273.
28. Gangloff YG, Pointud JC, Thuault S, Carre ´ L, Romier C, et al. (2001) The
TFIID components human TAF(II)140 and Drosophila BIP2 (TAF(II)155) are
novel metazoan homologues of yeast TAF(II)47 containing a histone fold and a
PHD finger. Molecular and cellular biology 21: 5109–5121. doi:10.1128/
MCB.21.15.5109–5121.2001.
29. Loo LWM, Cheng I, Tiirikainen M, Lum-Jones A, Seifried A, et al. (2012) cis-
Expression QTL Analysis of Established Colorectal Cancer Risk Variants in
Colon Tumors and Adjacent Normal Tissue. PloS one 7: e30477. doi:10.1371/
journal.pone.0030477.
30. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, et al. (1991) Mutations of
chromosome 5q21 genes in FAP and colorectal cancer patients. Science (New
York, NY) 253: 665–669.
31. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, et al. (1991)
Identification of a gene located at chromosome 5q21 that is mutated in
colorectal cancers. Science (New York, NY) 251: 1366–1370.
32. Lignitto L, Carlucci A, Sepe M, Stefan E, Cuomo O, et al. (2011) Control of
PKA stability and signalling by the RING ligase praja2. Nature cell biology 13:
412–422. doi:10.1038/ncb2209.
33. Yu P, Chen Y, Tagle DA, Cai T (2002) PJA1, encoding a RING-H2 finger
ubiquitin ligase, is a novel human X chromosome gene abundantly expressed in
brain. Genomics 79: 869–874. doi:10.1006/geno.2002.6770.
34. Misago M, Liao YF, Kudo S, Eto S, Mattei MG, et al. (1995) Molecular cloning
and expression of cDNAs encoding human alpha-mannosidase II and a
previously unrecognized alpha-mannosidase IIx isozyme. Proceedings of the
National Academy of Sciences of the United States of America 92: 11766–
11770.
35. Massague ´ J (2000) How cells read TGF-beta signals. Nature reviews Molecular
cell biology 1: 169–178. doi:10.1038/35043051.
36. Slattery ML, Lundgreen A, Herrick JS, Caan BJ, Potter JD, et al. (2011)
Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1
and eIF4E and riskof colon and rectal cancer: additional support for a TGF-b-
signaling pathway. Carcinogenesis 32: 318–326. doi:10.1093/carcin/bgq245.
37. Walther DJ, Peter J-U, Bashammakh S, Ho ¨rtnagl H, Voits M, et al. (2003)
Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science
(New York, NY) 299: 76. doi:10.1126/science.1078197.
38. Cattaneo MG, Codignola A, Vicentini LM, Clementi F, Sher E (1993) Nicotine
stimulates a serotonergic autocrine loop in human small-cell lung carcinoma.
Cancer research 53: 5566–5568.
39. Hambek M, Werner C, Baghi M, Gsto ¨ttner W, Knecht R (n.d.) Prestimulation
of head and neck cancer cells with growth factors enhances treatment efficacy.
Anticancer research 26: 1091–1095.
40. Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH, Thompson CS (2006)
The effect of serotonin and serotonin antagonists on bladder cancer cell
proliferation. BJU international 97: 634–639. doi:10.1111/j.1464–
410X.2006.06056.x.
41. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, et al. (2008) Serotonin
regulates macrophage-mediated angiogenesis in a mouse model of colon cancer
allografts. Cancer research 68: 5152–5158. doi:10.1158/0008–5472.CAN-08–
0202.
42. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more
efficient than replication-based analysis for two-stage genome-wide association
studies. Nature genetics 38: 209–213. doi:10.1038/ng1706.
43. Tao S, Feng J, Webster T, Jin G, Hsu F-C, et al. (2012) Genome-wide two-locus
epistasis scans in prostate cancer using two European populations. Human
genetics. doi:10.1007/s00439–012–1148–4.
44. Piegorsch WW, Weinberg CR, Taylor JA (1994) Non-hierarchical logistic
models and case-only designs for assessing susceptibility in population-based
case-control studies. Statistics in medicine 13: 153–162.
45. Yang Q, Khoury MJ, Sun F, Flanders WD (1999) Case-only design to measure
gene-gene interaction. Epidemiology (Cambridge, Mass) 10: 167–170.
46. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, et al. (2001) Linkage
disequilibrium in the human genome. Nature 411: 199–204. doi:10.1038/
35075590.
47. Bhattacharjee S, Chatterjee N, Wheeler W (2010) CGEN: An R package for
analysis of case-control studies in genetic epidemiology.
48. Prentice RL (2011) Empirical evaluation of gene and environment interactions:
methods and potential. Journal of the National Cancer Institute 103: 1209–
1210. doi:10.1093/jnci/djr279.
49. VanderWeele TJ, Laird NM (2011) Tests for compositional epistasis under single
interaction-parameter models. Annals of human genetics 75: 146–156.
doi:10.1111/j.1469–1809.2010.00600.x.
50. Kooperberg C, Leblanc M (2008) Increasing the power of identifying
gene6gene interactions in genome-wide association studies. Genetic epidemi-
ology 32: 255–263. doi:10.1002/gepi.20300.
51. Bureau A, Dupuis J, Falls K, Lunetta KL, Hayward B, et al. (2005) Identifying
SNPs predictive of phenotype using random forests. Genetic epidemiology 28:
171–182. doi:10.1002/gepi.20041.
52. Lunetta KL, Hayward LB, Segal J, Van Eerdewegh P (2004) Screening large-
scale association study data: exploiting interactions using random forests. BMC
genetics 5: 32. doi:10.1186/1471-2156-5-32.
53. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, et al. (2001)
Multifactor-dimensionality reduction reveals high-order interactions among
estrogen-metabolism genes in sporadic breast cancer. American journal of
human genetics 69: 138–147. doi:10.1086/321276.
54. VanderWeele TJ, Herna ´ndez-Dı ´az S, Herna ´n MA (2010) Case-only gene-
environment interaction studies: when does association imply mechanistic
interaction? Genetic epidemiology 34: 327–334. doi:10.1002/gepi.20484.
55. VanderWeele TJ (2009) Sufficient cause interactions and statistical interactions.
Epidemiology (Cambridge, Mass) 20: 6–13. doi:10.1097/EDE.0-
b013e31818f69e7.
56. Figueiredo JC, Lewinger JP, Song C, Campbell PT, Conti DV, et al. (2011)
Genotype-environment interactions in microsatellite stable/microsatellite insta-
bility-low colorectal cancer: results from a genome-wide association study.
Cancer epidemiology, biomarkers & prevention?: a publication of the American
Association for Cancer Research, cosponsored by the American Society of
Preventive Oncology 20: 758–766. doi:10.1158/1055–9965.EPI-10–0675.
57. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint
method for genome-wide association studies by imputation of genotypes. Nature
genetics 39: 906–913. doi:10.1038/ng2088.
58. Browning BL, Browning SR (2009) A unified approach to genotype imputation
and haplotype-phase inference for large data sets of trios and unrelated
individuals. American journal of human genetics 84: 210–223. doi:10.1016/
j.ajhg.2009.01.005.
59. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence
and genotype data to estimate haplotypes and unobserved genotypes. Genetic
epidemiology 34: 816–834. doi:10.1002/gepi.20533.
60. Nothnagel M, Ellinghaus D, Schreiber S, Krawczak M, Franke A (2009) A
comprehensive evaluation of SNP genotype imputation. Human genetics 125:
163–171. doi:10.1007/s00439–008–0606–5.
61. Go ¨gele M, Minelli C, Thakkinstian A, Yurkiewich A, Pattaro C, et al. (2012)
Methods for meta-analyses of genome-wide association studies: critical
assessment of empirical evidence. American journal of epidemiology 175:
739–749. doi:10.1093/aje/kwr385.
Genome-Wide Search for GxG in Colorectal Cancer
PLOS ONE | www.plosone.org 13 December 2012 | Volume 7 | Issue 12 | e5253562. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nature genetics 38: 904–909. doi:10.1038/ng1847.
63. Hsu L, Jiao S, Dai JY, Hutter C, Peters U, et al. (2012) Powerful Cocktail
Methods for Detecting Genome-Wide Gene-Environment Interaction. Genetic
Epidemiology 36: 183–194. doi:10.1002/gepi.21610.
64. Jiao S, Hsu L, Hutter CM, Peters U (2011) The use of imputed values in the
meta-analysis of genome-wide association studies. Genetic epidemiology 35:
597–605. doi:10.1002/gepi.20608.
Genome-Wide Search for GxG in Colorectal Cancer
PLOS ONE | www.plosone.org 14 December 2012 | Volume 7 | Issue 12 | e52535